Fresenius Medical Care AG & Co. KGaAFME
Mentioned
Impact on stocks 1
Health Care
Fresenius Medical Care AG & Co. KGaAFresenius Medical Care AG & Co. KGaAFresenius Medical Care shares fell 8.0% to €41.285 on Tuesday as investors focused on a 0.9% year-over-year decline in comparable same-market treatment volumes in the United States, overshadowing better-than-expected second-quarter results. The dialysis provider reported operating income excluding special items of €569 million, a 23% currency-adjusted increase that beat the consensus of €515 million, while revenue rose to €4.861 billion against forecasts of about €4.792 billion. JPMorgan analyst David Adlington kept an Underweight rating with a €37.40 price target, noting that management’s decision to reaffirm rather than raise full-year guidance could lead to lower second-half earnings estimates, and Jefferies analyst James Vane-Tempest maintained an Underperform recommendation with a €31 price target, citing weaker U.S. treatment volumes as the primary challenge. The stock opened at €41.16 and hit a session low of €40.555, ranking among the weakest performers in the DAX as the unchanged outlook triggered a sell-the-news reaction that reversed part of its recent recovery.
Fresenius Medical Care AG & Co. KGaA